Meeder Advisory Services Inc. Has $2.24 Million Stock Holdings in Bristol Myers Squibb Company (NYSE:BMY)

Meeder Advisory Services Inc. raised its stake in Bristol Myers Squibb Company (NYSE:BMY) by 5.4% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 36,727 shares of the biopharmaceutical company’s stock after purchasing an additional 1,882 shares during the quarter. Meeder Advisory Services Inc.’s holdings in Bristol Myers Squibb were worth $2,240,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of the stock. Capital International Investors grew its stake in Bristol Myers Squibb by 7.5% in the fourth quarter. Capital International Investors now owns 45,866,624 shares of the biopharmaceutical company’s stock valued at $2,593,940,000 after purchasing an additional 3,218,865 shares in the last quarter. Geode Capital Management LLC grew its stake in Bristol Myers Squibb by 2.7% in the fourth quarter. Geode Capital Management LLC now owns 44,391,247 shares of the biopharmaceutical company’s stock valued at $2,505,967,000 after purchasing an additional 1,187,231 shares in the last quarter. Ameriprise Financial Inc. grew its stake in Bristol Myers Squibb by 59.9% in the fourth quarter. Ameriprise Financial Inc. now owns 32,079,246 shares of the biopharmaceutical company’s stock valued at $1,814,341,000 after purchasing an additional 12,011,983 shares in the last quarter. Bank of New York Mellon Corp grew its stake in Bristol Myers Squibb by 8.6% in the first quarter. Bank of New York Mellon Corp now owns 26,865,073 shares of the biopharmaceutical company’s stock valued at $1,638,501,000 after purchasing an additional 2,131,205 shares in the last quarter. Finally, Northern Trust Corp grew its stake in Bristol Myers Squibb by 16.2% in the fourth quarter. Northern Trust Corp now owns 24,658,360 shares of the biopharmaceutical company’s stock valued at $1,394,677,000 after purchasing an additional 3,431,248 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

BMY has been the subject of several research analyst reports. William Blair reiterated a “market perform” rating on shares of Bristol Myers Squibb in a research note on Friday, April 25th. Morgan Stanley reduced their target price on Bristol Myers Squibb from $36.00 to $34.00 and set an “underweight” rating for the company in a research note on Thursday, July 10th. The Goldman Sachs Group reiterated a “neutral” rating and set a $55.00 target price (down from $67.00) on shares of Bristol Myers Squibb in a research note on Tuesday, April 8th. Argus upgraded Bristol Myers Squibb to a “hold” rating in a research note on Friday, April 25th. Finally, Cantor Fitzgerald reiterated a “neutral” rating and set a $55.00 target price on shares of Bristol Myers Squibb in a research note on Tuesday, April 22nd. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $58.53.

Bristol Myers Squibb Stock Performance

NYSE:BMY opened at $46.85 on Wednesday. The stock has a fifty day moving average price of $47.65 and a 200-day moving average price of $52.49. The company has a market cap of $95.35 billion, a price-to-earnings ratio of 17.55, a PEG ratio of 2.50 and a beta of 0.36. The company has a debt-to-equity ratio of 2.65, a quick ratio of 1.17 and a current ratio of 1.28. Bristol Myers Squibb Company has a fifty-two week low of $44.00 and a fifty-two week high of $63.33.

Bristol Myers Squibb Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, August 1st. Shareholders of record on Thursday, July 3rd will be given a $0.62 dividend. The ex-dividend date is Thursday, July 3rd. This represents a $2.48 annualized dividend and a yield of 5.29%. Bristol Myers Squibb’s dividend payout ratio is presently 92.88%.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.